A5083643588- Vasculitis and related conditions
- Otitis Media and Relapsing Polychondritis
- Systemic Lupus Erythematosus Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Systemic Sclerosis and Related Diseases
- Sarcoidosis and Beryllium Toxicity Research
- Hematological disorders and diagnostics
- Urticaria and Related Conditions
- Renal Diseases and Glomerulopathies
- Inflammatory Myopathies and Dermatomyositis
- Platelet Disorders and Treatments
- Atherosclerosis and Cardiovascular Diseases
- IgG4-Related and Inflammatory Diseases
- Inflammasome and immune disorders
- Monoclonal and Polyclonal Antibodies Research
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Streptococcal Infections and Treatments
- Eosinophilic Disorders and Syndromes
- Cell Adhesion Molecules Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Infectious Diseases and Tuberculosis
- Bone and Joint Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Skin Diseases and Diabetes
Universitair Ziekenhuis Leuven
2015-2025
KU Leuven
2016-2025
ERN GUARD-Heart
2022-2025
UCLouvain
2023
Bristol-Myers Squibb (Switzerland)
2022
Regeneron (United States)
2022
AstraZeneca (Brazil)
2022
Triangle
2022
Erasmus University Rotterdam
2011
General Department of Preventive Medicine
2007
Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of is associated with side effects. The effect interleukin-6 receptor alpha inhibitor tocilizumab on rates relapse during glucocorticoid tapering was studied in patients giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, a 2:1:1:1 ratio, to receive subcutaneous (at dose 162 mg) weekly or every other week, combined 26-week prednisone taper, placebo taper over period either...
Abstract Objective Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that usually treated with an extended course intravenous (IV) cyclophosphamide (CYC). Given the side effects this regimen, we evaluated efficacy and toxicity low‐dose IV CYC prescribed as remission‐inducing treatment, followed by azathioprine (AZA) remission‐maintaining treatment. Methods In multicenter, prospective clinical trial (the Euro‐Lupus Nephritis Trial [ELNT]), randomly assigned 90...
Background: Since testing for antineutrophil cytoplasmic antibodies (ANCA) became available routine evaluation, no large homogeneous cohort of patients with the Churg–Strauss syndrome has been studied. Objective: To define clinical and biological characteristics newly diagnosed syndrome, according to presence or absence ANCA. Design: Cross-sectional analysis manifestations participants who were enrolled in treatment trials between December 1995 2002. Setting: Multicenter study 63 centers...
Abstract Objective To study fluorodeoxyglucose (FDG) uptake in the different vascular beds and large joints of patients with giant cell arteritis (GCA) at diagnosis, during steroid treatment, relapse. Methods All consecutive admitted to our department a diagnosis GCA underwent FDG–positron emission tomography (PET) scan before treatment methylprednisolone was started. PET scans were repeated 3 6 months, if initial showed FDG uptake. scored 7 areas total score (TVS) calculated, ranging from 0...
Objective: To update the follow-up of Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. Patients methods: Data survival kidney function were prospectively collected during 10-year period 90 patients in ELNT, except 6 lost to follow-up. Results: Death, sustained doubling serum creatinine end-stage renal disease rates...
Background Long-term immunosuppressive treatment does not efficiently prevent relapses of lupus nephritis (LN). This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment. Methods A total 105 patients with proliferative LN were included. All received three daily intravenous pulses 750 mg methylprednisolone, followed by oral glucocorticoids and six fortnightly cyclophosphamide 500 mg. Based on...
<h3>Introduction</h3> The previously reported randomised controlled trial of a consensus regimen pulse cyclophosphamide suggested that it was as effective daily oral (DO) for remission induction antineutrophil cytoplasm autoantibodies-associated systemic vasculitis when both were combined with the same glucocorticoid protocol (CYCLOPS study (Randomised versus Cyclophosphamide therapy ANCA-associated Systemic Vasculitis published de groot K, harper L <i>et al</i> Ann Int Med 2009)). had...
Abstract Objective In the Euro‐Lupus Nephritis Trial (ELNT), 90 patients with lupus nephritis were randomly assigned to a high‐dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly escalating doses) or low‐dose IV CYC of 500 mg given at intervals weeks), each which was followed by azathioprine (AZA). After median followup 41 months, difference in efficacy between regimens not observed. The present analysis undertaken extend identify prognostic factors. Methods...
Abstract Objective To compare long and short durations of adjunctive cyclophosphamide for the treatment severe Churg‐Strauss syndrome (CSS). Methods In this prospective multicenter therapeutic trial, 48 patients with CSS at least 1 poor‐prognosis factor baseline were treated glucocorticoids either 12 or 6 intravenous pulses. Results At 8 years, complete remission rates side effects therapy comparable both groups. The overall difference in relapses was not significant between 12‐pulse 6‐pulse...
Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but associated with infections, malignancies and infertility. Mycophenolate mofetil (MMF) has shown high remission rates in small studies of AAV.We conducted a randomised controlled trial to investigate whether MMF was non-inferior cyclophosphamide AAV. 140 newly diagnosed patients were randomly assigned or pulsed cyclophosphamide. All received the same oral...
Objective To report the 10-year follow-up of MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy proliferative lupus nephritis, to test different definitions early response predictors long-term renal outcome. Methods In 2014, data on survival, kidney function, 24 h proteinuria, flares other outcomes were collected for 105 patients randomised between 2002 2006, except in 13 lost follow-up. Results Death (2 3 AZA MMF groups,...
Objective This multicentre study was performed to evaluate the diagnostic accuracy of a wide spectrum novel technologies nowadays available for detection myeloperoxidase (MPO) and proteinase 3 (PR3)-antineutrophil cytoplasmic antibodies (ANCAs). Methods Sera (obtained at time diagnosis) from 251 patients with ANCA-associated vasculitis (AAV), including granulomatosis polyangiitis microscopic polyangiitis, 924 disease controls were tested presence pattern/perinuclear pattern atypical ANCA...
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy GM-CSF receptor antagonist mavrilimumab maintaining disease remission. Methods This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed arteritis 50 centres (North America, Europe, Australia). Active within 6 weeks baseline was required for inclusion. Patients glucocorticoid-induced...
Epidemiological changes and the ongoing expansion of diagnostic armamentarium warrant a regular update spectrum diseases that present as prolonged febrile illnesses.We prospectively collected series 290 immunocompetent patients referred to our university hospital between 1990 1999 with illness (temperature >38.3 degrees C) uncertain cause, lasting at least 3 weeks. Patients were categorized in 4 groups according timing diagnosis: early diagnosis (within in-hospital days or outpatient...
To study the possible contribution of fluorodeoxyglucose (FDG)-positron emission tomography (PET) in diagnosis giant cell arteritis and polymyalgia rheumatica.A consecutive case series consisting five patients with rheumatica, six temporal 23 age-matched other inflammatory conditions were evaluated FDG-PET. Studies performed before therapy steroids was started.A total 4/6 4/5 had increased FDG uptake their thoracic vessels, compared to 1/23 controls (P < 0.001). Increased vascular upper legs...
To investigate a new therapeutic strategy, with rapid corticosteroid dose tapering and limited cyclophosphamide (CYC) exposure, for older patients systemic necrotizing vasculitides (SNVs; polyarteritis nodosa [PAN], granulomatosis polyangiitis [Wegnener's] [GPA], microscopic [MPA], or eosinophilic GPA [Churg-Strauss] [EGPA]).A multicenter, open-label, randomized controlled trial comprising ≥65 years old newly diagnosed as having SNV was conducted. The experimental treatment consisted of...